{"id":"https://openalex.org/W3122875367","doi":null,"title":"New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options","display_name":"New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options","alternate_titles":[],"publication_year":2011,"publication_date":"2011-01-01","ids":{"openalex":"https://openalex.org/W3122875367","mag":"3122875367"},"language":"en","primary_location":{"id":"mag:3122875367","doi":null,"is_oa":false,"landing_page_url":"https://ideas.repec.org/b/ohe/monogr/000184.html","pdf_url":null,"source":{"id":"https://openalex.org/S4306520202","display_name":"Monographs","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Monographs","raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W3122875367"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045431508","display_name":"Pallavi Raj Sharma","orcid":"https://orcid.org/0000-0003-3877-7272","observed_orcids":["https://orcid.org/0000-0003-3877-7272"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pallavi Raj Sharma","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3877-7272","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5108114814","display_name":"Adrian Towse","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Adrian Towse","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":4.4193,"has_fulltext":false,"cited_by_count":21,"citation_normalized_percentile":{"value":0.93936818,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":97},"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10897","display_name":"Antibiotic Use and Resistance","score":0.005400000140070915,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antimicrobial-resistance","display_name":"antimicrobial resistance","score":0.9990000128746033},{"id":"https://openalex.org/keywords/pharmaceutical-industry-incentives","display_name":"pharmaceutical industry incentives","score":0.47999998927116394},{"id":"https://openalex.org/keywords/advance-market-commitments","display_name":"advance market commitments","score":0.7680000066757202},{"id":"https://openalex.org/keywords/priority-review-voucher","display_name":"priority review voucher","score":0.984000027179718},{"id":"https://openalex.org/keywords/orphan-drug-policy","display_name":"orphan drug policy","score":0.7020000219345093},{"id":"https://openalex.org/keywords/eu-policy","display_name":"European Union policy","score":0.5730000138282776}],"concepts":[{"id":"https://openalex.org/C29122968","wikidata":"https://www.wikidata.org/wiki/Q1414816","display_name":"Incentive","level":2,"score":0.708773136138916},{"id":"https://openalex.org/C100001284","wikidata":"https://www.wikidata.org/wiki/Q2248246","display_name":"Public economics","level":1,"score":0.5820488929748535},{"id":"https://openalex.org/C75480439","wikidata":"https://www.wikidata.org/wiki/Q1367466","display_name":"Orphan drug","level":2,"score":0.5507649779319763},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.5350177884101868},{"id":"https://openalex.org/C2776034101","wikidata":"https://www.wikidata.org/wiki/Q1509347","display_name":"Commission","level":2,"score":0.5053487420082092},{"id":"https://openalex.org/C145097563","wikidata":"https://www.wikidata.org/wiki/Q1148747","display_name":"Payment","level":2,"score":0.48358339071273804},{"id":"https://openalex.org/C2910001868","wikidata":"https://www.wikidata.org/wiki/Q458","display_name":"European union","level":2,"score":0.47428494691848755},{"id":"https://openalex.org/C94665300","wikidata":"https://www.wikidata.org/wiki/Q63391344","display_name":"Antibiotic resistance","level":3,"score":0.4398939609527588},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.4370276927947998},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.2818775773048401},{"id":"https://openalex.org/C105639569","wikidata":"https://www.wikidata.org/wiki/Q582577","display_name":"Economic policy","level":1,"score":0.18823623657226562},{"id":"https://openalex.org/C10138342","wikidata":"https://www.wikidata.org/wiki/Q43015","display_name":"Finance","level":1,"score":0.13804808259010315},{"id":"https://openalex.org/C501593827","wikidata":"https://www.wikidata.org/wiki/Q12187","display_name":"Antibiotics","level":2,"score":0.11097455024719238},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.0},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.0},{"id":"https://openalex.org/C175444787","wikidata":"https://www.wikidata.org/wiki/Q39072","display_name":"Microeconomics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:3122875367","doi":null,"is_oa":false,"landing_page_url":"https://ideas.repec.org/b/ohe/monogr/000184.html","pdf_url":null,"source":{"id":"https://openalex.org/S4306520202","display_name":"Monographs","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Monographs","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.8371999859809875,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2803062031","https://openalex.org/W2800868568","https://openalex.org/W2068254771","https://openalex.org/W4256592006","https://openalex.org/W4385357997","https://openalex.org/W6996854520","https://openalex.org/W7090772650","https://openalex.org/W4390125580","https://openalex.org/W3011322138","https://openalex.org/W7047673995"],"abstract_inverted_index":{"Antimicrobial":[0],"resistance":[1],"(AMR)":[2],"to":[3,124,136,142,165],"drugs":[4],"is":[5],"a":[6,110,157,160,194,199],"natural":[7],"and":[8,39,96,117,127],"unavoidable":[9],"consequence":[10],"of":[11,25,36,54,67,71,87,131,183,188,205,212,219],"treating":[12,27],"infectious":[13,30,47],"diseases.":[14],"A":[15],"growing":[16],"global":[17],"public":[18],"health":[19],"threat,":[20],"AMR":[21],"reduces":[22],"the":[23,34,50,57,62,65,69,74,85,92,104,114,129,132,154,186,210],"chances":[24],"successfully":[26],"patients":[28],"with":[29,80],"diseases,":[31],"thereby":[32],"increasing":[33],"probability":[35],"complications,":[37],"morbidity":[38],"mortality.":[40],"The":[41],"World":[42],"Health":[43],"Organization":[44],"estimates":[45],"that":[46,98,112,120,166],"diseases":[48],"are":[49,145],"third":[51],"leading":[52],"cause":[53],"death":[55],"in":[56,185],"European":[58],"Union.":[59],"In":[60,89],"2009,":[61],"EU":[63,75],"emphasized":[64],"importance":[66],"encouraging":[68],"development":[70],"new":[72,100],"antibacterials;":[73],"Commission":[76],"has":[77],"been":[78],"tasked":[79],"developing":[81],"comprehensive":[82],"proposals":[83],"by":[84],"end":[86],"2012.":[88],"this":[90],"publication,":[91],"authors":[93,155],"provide":[94],"information":[95],"recommendations":[97],"offer":[99],"insight":[101],"into":[102],"addressing":[103],"core":[105],"issues.":[106],"This":[107],"monograph":[108],"outlines":[109],"model":[111],"assesses":[113],"push,":[115],"pull":[116],"hybrid":[118,161],"approaches":[119],"could":[121],"be":[122,174],"applied":[123],"encourage":[125],"innovation":[126],"suggest":[128],"size":[130],"various":[133],"incentives":[134,207],"needed":[135],"make":[137],"antibiotic":[138],"R&D":[139],"as":[140,144],"attractive":[141],"developers":[143],"other":[146],"therapeutic":[147],"drug":[148],"classes.":[149],"Based":[150],"on":[151],"these":[152,206],"analyses,":[153],"express":[156],"preference":[158],"for":[159,168,177,181],"push-pull":[162],"policy":[163],"similar":[164],"used":[167],"orphan":[169],"drugs.":[170],"An":[171],"alternative":[172],"might":[173],"upfront":[175],"payment":[176],"registration":[178],"(rather":[179],"than":[180],"volume":[182,218],"use)":[184],"form":[187],"an":[189,213],"advance":[190],"market":[191],"commitment":[192],"'prize',":[193],"priority":[195],"review":[196],"voucher":[197],"or":[198],"transferable":[200],"intellectual":[201],"property":[202],"extension.":[203],"Each":[204],"would":[208],"reward":[209],"launch":[211],"effective":[214],"drug,":[215],"making":[216],"actual":[217],"use":[220],"less":[221],"relevant.":[222]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W3122875367","counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2021-02-01T00:00:00"}
